Evaluation of the Potential of Self-Nanoemulsifying Drug Delivery System (SNEDDS) in Increasing Oral Bioavailability of Low-Solubility Drugs
DOI:
https://doi.org/10.69855/farmasi.v2i1.544Keywords:
SNEDDS, Losartan Potassium, Nanoemulsion, Oral Bioavailability, Lipid-Based Drug DeliveryAbstract
Losartan potassium, a Biopharmaceutics Classification System (BCS) Class II drug, exhibits poor aqueous solubility and limited oral bioavailability. This study aimed to develop and optimize a Self-Nanoemulsifying Drug Delivery System (SNEDDS) to enhance its dissolution and absorption. SNEDDS formulations were prepared using Capmul MCM C8, Tween 80, and PEG 400 based on solubility screening and ternary phase diagram analysis. The optimized formulation (F3) was evaluated for droplet size, polydispersity index (PDI), in vitro drug release, pharmacokinetics, and stability. Pharmacokinetic studies were conducted in experimental rats Pharmacokinetic studies were conducted in experimental rats (n = 3 per group) to assess bioavailability. The optimized SNEDDS produced nanoemulsions with a droplet size of 68.3 nm, low PDI, and good dilution stability. In vitro studies demonstrated rapid drug release (>96% within 30 minutes), significantly higher than the plain suspension. Pharmacokinetic results showed a 3.09-fold increase in bioavailability and a 2.79-fold increase in Cmax without altering Tmax. Stability studies confirmed good physicochemical stability over six months under ICH conditions. In conclusion, SNEDDS is a promising strategy to improve the oral bioavailability of poorly water-soluble drugs such as losartan potassium.
References
BPOM. (2021). Guidelines for preclinical studies. National Agency of Drug and Food Control.
Dressman, J. B., & Reppas, C. (2010). Oral drug absorption: Prediction and assessment (2nd ed.). Informa Healthcare.
ICH. (2003). Stability testing of new drug substances and products Q1A(R2). International Council for Harmonisation.
Kalepu, S., & Nekkanti, V. (2015). Insoluble drug delivery strategies: Recent advances and business prospects. Acta Pharmaceutica Sinica B, 5(5), 442–453.
Kassem, M. A., ElMeshad, A. N., & Fares, A. R. (2017). Enhanced bioavailability of self-nanoemulsifying drug delivery systems (SNEDDS): Recent advances and applications. Drug Development and Industrial Pharmacy, 43(10), 1674–1686.
Kaur, G., Beg, S., Katare, O. P., & Singh, B. (2020). Recent advances in SNEDDS for improving oral bioavailability. European Journal of Pharmaceutical Sciences, 152, 105–118.
Kaur, R., Kumar, S., & Sharma, S. (2020). Development and evaluation of SNEDDS of losartan potassium. Journal of Drug Delivery Science and Technology, 57, 101–110.
Linn, M., Collnot, E. M., Djuric, D., et al. (2012). Soluplus as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. European Journal of Pharmaceutical Sciences, 45(3), 336–343.
Murad, R. A., Al-Ani, I. M., & Al-Obaidi, H. J. (2020). Recent advances in self-nanoemulsifying drug delivery systems for poorly soluble drugs. Journal of Drug Delivery Science and Technology, 55, 101–115.
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery, 6(3), 231–248.
Rao, S. V. R., Yajurvedi, K., & Shao, J. (2020). Lipid-based drug delivery systems: Current advances and future perspectives. International Journal of Pharmaceutics, 590, 119–134.
Sherif, A. Y., El-Say, K. M., & Ahmed, T. A. (2024). Lipid-based nanocarriers for oral drug delivery: Recent trends and future perspectives. Pharmaceutics, 16(2), 210.
Tran, T. H., Nguyen, H. T., Pham, T. T., et al. (2021). Development of SNEDDS for improving dissolution and oral bioavailability of poorly soluble drugs: Recent insights. Pharmaceutics, 13(6), 865.
Usta, B., et al. (2025). Advances in lipid-based formulations for enhancing oral bioavailability of poorly soluble drugs. International Journal of Pharmaceutics, 640, 123–135.
Zhang, J., Liu, H., Wen, T., et al. (2014). Enhancement of oral bioavailability of losartan potassium by SNEDDS. Pharmaceutical Development and Technology, 19(5), 600–608.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Muhammad Nurul Fadel, Emma Jayanti Besan, Dzukharian Munandar, Husnunnisa, Cut Intan Annisa Puteri
This work is licensed under a Creative Commons Attribution 4.0 International License.
